[HTML][HTML] Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
DS Boyer, YH Yoon, R Belfort Jr, F Bandello, RK Maturi… - Ophthalmology, 2014 - Elsevier
DS Boyer, YH Yoon, R Belfort Jr, F Bandello, RK Maturi, AJ Augustin, XY Li, H Cui…
Ophthalmology, 2014•ElsevierPurpose To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex,
DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema
(DME). Design Two randomized, multicenter, masked, sham-controlled, phase III clinical
trials with identical protocols were conducted. Data were pooled for analysis. Participants
Patients (n= 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen
equivalent, and central retinal thickness (CRT) of≥ 300 μm by optical coherence …
DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema
(DME). Design Two randomized, multicenter, masked, sham-controlled, phase III clinical
trials with identical protocols were conducted. Data were pooled for analysis. Participants
Patients (n= 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen
equivalent, and central retinal thickness (CRT) of≥ 300 μm by optical coherence …
Purpose
To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema (DME).
Design
Two randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical protocols were conducted. Data were pooled for analysis.
Participants
Patients (n = 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen equivalent, and central retinal thickness (CRT) of ≥300 μm by optical coherence tomography.
Methods
Patients were randomized in a 1:1:1 ratio to study treatment with DEX implant 0.7 mg, DEX implant 0.35 mg, or sham procedure and followed for 3 years (or 39 months for patients treated at month 36) at ≤40 scheduled visits. Patients who met retreatment eligibility criteria could be retreated no more often than every 6 months.
Main Outcome Measures
The predefined primary efficacy endpoint for the United States Food and Drug Administration was achievement of ≥15-letter improvement in BCVA from baseline at study end. Safety measures included adverse events and intraocular pressure (IOP).
Results
Mean number of treatments received over 3 years was 4.1, 4.4, and 3.3 with DEX implant 0.7 mg, DEX implant 0.35 mg, and sham, respectively. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end was greater with DEX implant 0.7 mg (22.2%) and DEX implant 0.35 mg (18.4%) than sham (12.0%; P ≤ 0.018). Mean average reduction in CRT from baseline was greater with DEX implant 0.7 mg (−111.6 μm) and DEX implant 0.35 mg (−107.9 μm) than sham (−41.9 μm; P < 0.001). Rates of cataract-related adverse events in phakic eyes were 67.9%, 64.1%, and 20.4% in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham groups, respectively. Increases in IOP were usually controlled with medication or no therapy; only 2 patients (0.6%) in the DEX implant 0.7 mg group and 1 (0.3%) in the DEX implant 0.35 mg group required trabeculectomy.
Conclusions
The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA. The safety profile was acceptable and consistent with previous reports.
Elsevier